問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Radiation Therapy

Division of Hematology & Oncology

Digestive System Department

Division of Thoracic Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-11-06

洪逸平Hung, Yi-Ping
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

132Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

洪逸平

List

204Cases

2021-12-27 - 2026-01-17

Phase II/III

Active
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    輸注液

Participate Sites
7Sites

Recruiting7Sites

2021-10-01 - 2022-08-24

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-03-31 - 2028-05-06

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-09-01 - 2024-12-11

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-06-01 - 2020-05-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-01-03 - 2023-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-08-01 - 2025-06-30

Phase II

Completed
A Phase II Randomized Placebo Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    tablets

Participate Sites
7Sites

Terminated7Sites

2022-04-01 - 2028-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-12-01 - 2025-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-12-22 - 2030-10-25

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 7 8 9 10 11 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB